Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and more

April 25, 2026 06:00 AM EDTUpdated 10:08 AM Weekly Sanofi’s im­munol­o­gy reck­on­ing; Lil­ly ac­quires in vi­vo CAR-T biotech; RevMed’s ‘Her­ceptin mo­ment’; and more Max Gelman Senior Editor Wel­come back to an­oth­er edi­tion of End­points Week­ly! We’re do­ing a lit­tle bit of cel­e­brat­ing here at End­points, as we took home Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER